Liver transplantation for fulminant hepatic failure

Thiel, David H. Van; Brems, John J.; Nadir, Abdul; İdilman, Ramazan; Colantoni, Alessandra; Holt, David R.; Edelstein, Steven B.

doi:10.1007/bf02990105

Cited by 23 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most serious characteristic is very high mortality (60% to 80%) due to the effects of a variety of complications and lack of effective therapies [1,2]. At present, no specific therapy is available other than liver transplantation [3,4]. Therefore, there is an urgent need for effective therapy for fulminant hepatic failure.…”

Section: Introductionmentioning

confidence: 98%

Protective Effect of Neutrophil Elastase Inhibitor (FR136706) in Lethal Acute Liver Failure Induced by D-Galactosamine and Lipopolysaccharide in Rats

Uchida

Kaibori

Hijikawa

et al. 2008

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Protective Effect of Neutrophil Elastase Inhibitor (FR136706) in Lethal Acute Liver Failure Induced by D-Galactosamine and Lipopolysaccharide in Rats

Uchida

Kaibori

Hijikawa

et al. 2008

Journal of Surgical Research

View full text Add to dashboard Cite

“…The most serious characteristic is very high mortality (60-80%) due to the effects of a variety of complications and lack of effective therapies [1,2]. At present no specific therapy is available other than liver transplantation [3,4]. Therefore, there is an urgent need for effective therapy for fulminant hepatic failure.…”

Section: Introductionmentioning

confidence: 98%

Na+/H+ exchanger inhibitor, FR183998, has protective effect in lethal acute liver failure and prevents iNOS induction in rats

Tanaka

Uchida

Kaibori

et al. 2008

Journal of Hepatology

View full text Add to dashboard Cite

“…However, the only clinical treatment for FHF is liver transplantation, which is limited by a shortage of donor livers [1]. …”

Section: Introductionmentioning

confidence: 99%

Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure

et al. 2017

View full text Add to dashboard Cite

BackgroundHuman menstrual blood-derived stem cells (MenSCs) are a novel source of MSCs that provide the advantage of being easy to collect and isolate. Exosomes contain some mRNAs and adhesion molecules that can potentially impact cellular and animal physiology. This study aimed to investigate the therapeutic potential of MenSC-derived exosomes (MenSC-Ex) on AML12 cells (in vitro) and D-GalN/LPS-induced FHF mice (in vivo).MethodsTransmission electron microscopy and Western blot were used to identify MenSC-Ex. Antibody array was used to examine cytokine levels on MenSC-Ex. MenSC-Ex were treated in D-GalN/LPS-induced AML12 in vitro. Cell proliferation and apoptosis were measured. MenSC-Ex were injected into the tail veins of mice 24 h before treatment with D-GalN/LPS. Blood and liver tissues served as physiological and biochemical indexes. The number of liver mononuclear cells (MNCs) and the amount of the active apoptotic protein caspase-3 were determined to elaborate the mechanism of hepatoprotective activity.ResultsHuman menstrual blood-derived stem cell-derived exosomes (MenSC-Ex) are bi-lipid membrane vesicles that have a round, ball-like shape with a diameter of approximately 30–100 nm. Cytokine arrays have shown that MenSC-Ex expressed cytokines, including ICAM-1, angiopoietin-2, Axl, angiogenin, IGFBP-6, osteoprotegerin, IL-6, and IL-8. MenSC-Ex markedly improved liver function, enhanced survival rates, and inhibited liver cell apoptosis at 6 h after transplantation. MenSC-Ex migrated to sites of injury and to AML12 cells (a mouse hepatocyte cell line), respectively. Moreover, MenSC-Ex reduced the number of liver mononuclear cells (MNCs) and the amount of the active apoptotic protein caspase-3 in injured livers.ConclusionsIn conclusion, our results provide preliminary evidence for the anti-apoptotic capacity of MenSC-Ex in FHF and suggest that MenSC-Ex may be an alternative therapeutic approach to treat FHF.Electronic supplementary materialThe online version of this article (doi:10.1186/s13287-016-0453-6) contains supplementary material, which is available to authorized users.

show abstract

Liver transplantation for fulminant hepatic failure

Abstract: The etiology and prognosis of individuals with various forms of fulminant hepatic failure are reviewed. Special techniques of clinical management and decision making as to when and to whom to transplant in cases of fulminant hepatic failure are reviewed.

Cited by 23 publications

References 14 publications

Protective Effect of Neutrophil Elastase Inhibitor (FR136706) in Lethal Acute Liver Failure Induced by D-Galactosamine and Lipopolysaccharide in Rats

Protective Effect of Neutrophil Elastase Inhibitor (FR136706) in Lethal Acute Liver Failure Induced by D-Galactosamine and Lipopolysaccharide in Rats

Na+/H+ exchanger inhibitor, FR183998, has protective effect in lethal acute liver failure and prevents iNOS induction in rats

Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure

Contact Info

Product

Resources

About